Today: 21 July 2026
Browse Category

Health News 23 August 2025 - 12 December 2025

McCain Pizza Pockets Recall Australia 2025: Cheese & Bacon 400g Pulled from Woolworths, Coles and IGA After Plastic and Metal Contamination Warning

McCain Pizza Pockets Recall Australia 2025: Cheese & Bacon 400g Pulled from Woolworths, Coles and IGA After Plastic and Metal Contamination Warning

Australians are being urged to check their freezers after McCain Foods Pty Ltd issued a nationwide recall for McCain Cheese & Bacon Pizza Pockets following reports of foreign material in the product. The recall, published on Friday, 12 December 2025, covers items sold through major supermarkets and online deliveries across the country. Food Standards Australia New Zealand+1
12 December 2025
···
Costco Issues Urgent Recall of Caesar Salad and Chicken Sandwich Over Plastic Contamination Risk (November 25, 2025)

Costco Issues Urgent Recall of Caesar Salad and Chicken Sandwich Over Plastic Contamination Risk (November 25, 2025)

As of Tuesday, November 25, 2025, Costco is still urging members to stop eating certain ready‑to‑eat Caesar salad products after plastic fragments were found in the dressing packets used in those meals. The nationwide warehouse chain has recalled two popular deli items — its prepared Caesar Salad and Chicken Sandwich with Caesar Salad — in cooperation with dressing supplier Ventura Foods, following a member letter first posted on November 7. cdn.bfldr.com+2EatingWell+2
25 November 2025
·
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran, its in vivo CRISPR therapy for transthyretin amyloidosis. The FDA’s clinical holds on MAGNITUDE and MAGNITUDE‑2 are still in effect pending a formal hold letter. GlobeNewswire+1
7 November 2025
···
Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

Egg supplies and prices remain the backdrop to this story. 163 million U.S. poultry have died from avian flu since 2022, cutting the egg-laying flock by ~11% vs. 2019 reuters.com. Consumers have seen sticker shock – in some cities eggs cost $8–$10 per dozen reuters.com. This summer’s massive recall is partly why the FDA reclassified it at the top risk level newsweek.com foodnetwork.com.
22 October 2025
·
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL’s stock price exploded after the company announced a strategic alliance with Samsung on October 16. Under the deal, Samsung C&T will invest $110 million in GRAIL and become the exclusive distributor of the Galleri multi-cancer blood test in South Korea, with rights to expand into Japan and Singaporets2.tech. Samsung Electronics is also participating and plans to explore AI and health-data collaborations with GRAILts2.tech. This marks a major vote of confidence from one of Asia’s largest conglomerates. The partnership is expected to close by early 2026 and gives GRAIL a powerful commercialization partner in key Asian marketstradingview.com.
20 October 2025
···
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare FDA Commissioner’s National Priority Voucher for cytisinicline’s vaping cessation indication investing.com. This rally propelled the shares to multi-month highs in the mid-$3 range. Earlier in the week, ACHV had already begun gaining momentum – on Oct. 15 the stock broke above its 200-day moving average and hit $3.19 marketbeat.com, a bullish technical signal. As of Thursday’s close, the stock was at $3.08, up roughly 10% over the past month and far outperforming the broader market investing.com.
17 October 2025
··
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge stocktwits.com. The one-day drop – Kenvue’s worst on record – was triggered by headline risks that blindsided investors. By early Friday, October 17, the stock stabilized slightly after the rout stocktwits.com. Still, at roughly 40% below its IPO price, the Johnson & Johnson spinoff has seen its market capitalization shrink to about $30–31 billion reuters.com.
17 October 2025
···
INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility’s stock took investors on a wild ride on Oct. 16, skyrocketing almost 90% by the closing bellreuters.com. Shares opened at just $0.75 and, in an astonishing surge, hit $1.43 by day’s endreuters.com. To put the move in perspective, INVO’s daily gain far outpaced the broader market, and such a jump is highly unusual – even in the volatile biotech sector. Trading volume exploded to over 108 million sharesreuters.com, dwarfing the typical daily volume and exceeding the company’s entire share float many times overreuters.comstocktitan.net. This indicates a tidal wave of speculative interest flooded into the tiny stock.
16 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Koreainvesting.comprnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&Tprnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company advances toward test reimbursement globallyinvesting.comprnewswire.com. Under the LOI, definitive agreements are expected in early 2026, with testing operations to begin soon after closingprnewswire.cominvesting.com.
16 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours trading to roughly $0.36 on the cancer data announcement benzinga.com benzinga.com. That rally brought the stock briefly near its 30-day resistance around $0.26 ainvest.com. Before this spike, GNPX had been trading around $0.20. Over the last five trading days the stock was up about 25.6%, although year‐to‐date it was still down roughly 70% benzinga.com. For context, GNPX’s 52-week high is ~$4.09 and its 52-week low is about $0.22 google.com benzinga.com.
15 October 2025
···
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences’ stock has been on a wild ride in early October 2025. Heading into this period, SPRB was a little-known micro-cap biotech trading in the high single digits. At the close on Oct 3, 2025, shares stood at $8.82stocktitan.net after a period of relatively low activity. That calm shattered on Oct 6, when news of an FDA breakthrough designation sent the stock skyrocketing. SPRB opened the day with a huge gap up and at one point surged by 250–300% intraday, hitting roughly $31–$32 per sharebenzinga.comstocktwits.com. Benzinga reported Spruce trading around $31.50 by midday on the 6thbenzinga.com, and Stocktwits noted an extreme burst of bullish sentiment as the stock more than quadrupled at one pointstocktwits.com.
6 October 2025
··
‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

“Stratus” is the colloquial name for XFG, a recombinant Omicron descendant. WHO added XFG to its monitoring list in late June and, based on available evidence, concluded the “additional public‑health risk … is low.” WHO’s lab summary notes spike‑protein changes that can modestly increase immune escape compared with earlier JN.1‑family strains. World Health Organization
28 September 2025
Possible Life on Mars, ‘Black Hole Stars’ and a Global Diabetes Bombshell – Science News Roundup (Sept 15–16, 2025)

Possible Life on Mars, ‘Black Hole Stars’ and a Global Diabetes Bombshell – Science News Roundup (Sept 15–16, 2025)

In a sensational development for astrobiology, NASA announced that Perseverance has collected a Mars rock sample that “could preserve evidence of ancient microbial life” nasa.gov. The rover drilled the sample, nicknamed “Sapphire Canyon,” from an ancient riverbed formation rich in clay – exactly the kind of environment that on Earth traps and preserves organic remains nasa.gov nasa.gov. Inside the rock, scientists detected certain organic molecules and chemical patterns that are considered potential biosignatures, meaning they might be remnants of past life nasa.gov nasa.gov. Acting NASA Administrator Sean Duffy hailed the finding as “the closest we have ever come to discovering life on Mars”, calling it a “groundbreaking discovery” that advances our understanding of the Red Planet nasa.gov.
16 September 2025
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be that first line of defence,” said Dr. Adam Braunschweig of CUNY, who led the study gavi.org. The findings, published in Science Advances, mark an early proof-of-concept for broad-spectrum antivirals, though further work is needed to advance these candidates into animal and human trials. Experts note this approach could be game-changing in future pandemics, filling the gap while vaccines and virus-specific drugs are developed gavi.org.
30 August 2025
····
COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

Updated COVID Boosters Get Narrow Nod: The U.S. FDA approved new fall COVID-19 booster shots from Pfizer/BioNTech and Moderna on August 27 – but with strict eligibility limits. Only adults 65+ and younger people with certain medical conditions are cleared for the updated vaccines, and emergency use authorizations for routine use in healthy children were removed realeconomy.rsmus.com. Health experts immediately sounded alarms: the Infectious Diseases Society of America blasted the “narrowed” booster rollout as contrary to scientific guidance and a risk to lives cidrap.umn.edu. They warn these restrictions could hinder access, especially for children, and leave vulnerable groups exposed heading into respiratory virus season realeconomy.rsmus.com. Despite the controversy, U.S. health authorities insist the targeted approach is appropriate while uptake of prior boosters was low. All eyes are now on the CDC’s recommendations and whether insurers will cover off-label use to broaden protection.
29 August 2025
·
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s Interius acquisition reuters.com and Interius press release interiusbio.com; PharmExec on XOMA-Mural deal ts2.tech; Reuters – J&J $2B NC facility and quote ts2.tech ts2.tech; Reuters – Apollo Hospitals stake sale ts2.tech; BiopharmaTrend on Kyorin adopting Elix AI platform biopharmatrend.com biopharmatrend.com; Laotian Times – Amgen Golden Ticket and quote ts2.tech ts2.tech; Allos Pharma press release on arbaclofen rights & Dr. Carpenter quote allospharma.com allospharma.com; Allos press – ASD trial results allospharma.com; BiopharmaDive on VC funding and Kriya Therapeutics raise ts2.tech; Neurology Live – Hearing aids & dementia study ts2.tech ts2.tech; NIH news – Phantom limb cortical maps ts2.tech ts2.tech; WHO/UN joint release – Gaza famine declaration who.int; WHO/WMO report on heat stress who.int; Drug Target Review – Chikungunya outbreak global spread drugtargetreview.com drugtargetreview.com; KFF Health News/Washington Post – CDC layoffs & HHS staff letter kffhealthnews.org kffhealthnews.org.
23 August 2025
·······
1 2 3 4
Go toTop